BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Front Immunol 2020;11:472. [PMID: 32296421 DOI: 10.3389/fimmu.2020.00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Deak P, Knight R, Esser-kahn A. Robust tolerogenic dendritic cells via push/pull pairing of toll-like-receptor agonists and immunomodulators reduces EAE. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121571] [Reference Citation Analysis]
2 Jindal A, Sarkar S, Alam A. Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics. Front Chem 2021;9:629635. [PMID: 33708759 DOI: 10.3389/fchem.2021.629635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lee EK, Park YJ. Best Achievements in Clinical Thyroidology in 2020. Endocrinol Metab (Seoul) 2021;36:30-5. [PMID: 33677923 DOI: 10.3803/EnM.2021.103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moorman CD, Sohn SJ, Phee H. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy. Front Immunol 2021;12:657768. [PMID: 33854514 DOI: 10.3389/fimmu.2021.657768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rodriguez-Fernandez S, Almenara-Fuentes L, Perna-Barrull D, Barneda B, Vives-Pi M. A century later, still fighting back: antigen-specific immunotherapies for type 1 diabetes. Immunol Cell Biol 2021;99:461-74. [PMID: 33483995 DOI: 10.1111/imcb.12439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Maulloo CD, Cao S, Watkins EA, Raczy MM, Solanki AS, Nguyen M, Reda JW, Shim HN, Wilson DS, Swartz MA, Hubbell JA. Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance. Front Immunol 2021;12:714842. [PMID: 34630389 DOI: 10.3389/fimmu.2021.714842] [Reference Citation Analysis]
7 Watkins EA, Antane JT, Roberts JL, Lorentz KM, Zuerndorfer S, Dunaif AC, Bailey LJ, Tremain AC, Nguyen M, De Loera RC, Wallace RP, Weathered RK, Kontos S, Hubbell JA. Persistent antigen exposure via the eryptotic pathway drives terminal T cell dysfunction. Sci Immunol 2021;6:eabe1801. [PMID: 33637595 DOI: 10.1126/sciimmunol.abe1801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zheng J, Wu J, Ding X, Shen HC, Zou G. Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorg Med Chem Lett 2021;38:127862. [PMID: 33609659 DOI: 10.1016/j.bmcl.2021.127862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]